Objective: The Pharmacology Shared Resource supports pharmacokinetic (PK) study planning and analysis for both basic and clinical research projects of University of Colorado Cancer Center (UCCC) members. Services and Technologies: Services offered include: (1) PK study design consultation;(2) Development, validation and implementation of appropriate analytical assays for drugs in biological fluids and tissues;and (3) PK modeling and mathematical analysis of analytical data. Quantitative analytical methods employed by the Pharmacology Shared Resource include UV/Vis and fluorescent detection HPLC, LC tandem mass spectrometry, and other biochemical methodologies (i.e. ELISA, enzymatic). PK modeling services include systems-based approaches (non-compartmental modeling), compartmental modeling, physiologically-based and population-based analyses. The Pharmacology Shared Resource, houses two ABI3200 linear trap triple quadropole instruments with LC systems (Agilent 1200 or Shimadzu LC20) and HTC-PAL autosamplers, a Shimadzu Prominence LC system with UV/Vis (SPD-M20A) and fluorescence detection (RF-IOAxl) and refrigerated autosampler (S1L20AC). Consultation: The Pharmacology Shared Resource provides consultation to help members with little pharmacology or PK background to design appropriate experiments and analyze PK data. Utilization: Cancer Center members in the Developmental Therapeutics Program are the primary users of the Pharmacology Shared Resource;however, members of the Hormone Related Malignancies, Lung, Head &Neck Cancer and Cancer Prevention &Control Programs are also regular users. The Pharmacology Shared Resource moved to CSU from the Anschutz Medical Campus in 2007 and since then, utilization by UCCC members has increased annually while use by non-UCCC members has remained constant. Since the last competitive application in 2005, the Pharmacology Shared Resource has supported 39 UCCC investigators from across the consortium institutions and 24 non-UCCC members. In the last two years, 14 research projects and 10 clinical protocols from UCCC members have been supported. Management and Finances: This resource is UCCC-managed. Currently, 73.5% of the operating budget comes from charge backs to UCCC members who represent 62% of facility users. The Pharmacology Shared Resource requests $115K CCSG support for 34% of its operating budget.

Public Health Relevance

The Pharmacology Shared resource gathers technology and expertise to fully support pharmacology aspects of UCCC members'preclinical or clinical research, including pharmacokinetic (PK) study design, analytical assay design and development appropriate for measuring drugs in biological samples, expertise in animal dosing and sampling, and PK modeling.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-24
Application #
8465413
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-06
Project End
2017-01-31
Budget Start
2012-08-06
Budget End
2013-01-31
Support Year
24
Fiscal Year
2012
Total Cost
$137,271
Indirect Cost
$46,587
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Tuttle, Kathryn D; Krovi, S Harsha; Zhang, Jingjing et al. (2018) TCR signal strength controls thymic differentiation of iNKT cell subsets. Nat Commun 9:2650
Keysar, Stephen B; Eagles, Justin R; Miller, Bettina et al. (2018) Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clin Cancer Res 24:2935-2943
Salmon, Loïc; Stull, Frederick; Sayle, Sabrina et al. (2018) The Mechanism of HdeA Unfolding and Chaperone Activation. J Mol Biol 430:33-40
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
Steckelberg, Anna-Lena; Akiyama, Benjamin M; Costantino, David A et al. (2018) A folded viral noncoding RNA blocks host cell exoribonucleases through a conformationally dynamic RNA structure. Proc Natl Acad Sci U S A 115:6404-6409
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Antonioli, Alexandra H; White, Janice; Crawford, Frances et al. (2018) Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol 200:316-326
Boswell, Zachary K; Rahman, Samiur; Canny, Marella D et al. (2018) A dynamic allosteric pathway underlies Rad50 ABC ATPase function in DNA repair. Sci Rep 8:1639
Fitzwalter, Brent E; Towers, Christina G; Sullivan, Kelly D et al. (2018) Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Dev Cell 44:555-565.e3
Duex, Jason E; Swain, Kalin E; Dancik, Garrett M et al. (2018) Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. Mol Cancer Res 16:69-77

Showing the most recent 10 out of 1634 publications